Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
Potential therapeutic effects of curcumin mediated by JAK/STAT signaling pathway: a review
M Ashrafizadeh, H Rafiei… - Phytotherapy …, 2020 - Wiley Online Library
Curcumin is a naturally occurring nutraceutical compound with a number of therapeutic and
biological activities such as antioxidant, anti‐inflammatory, anti‐diabetic, antitumor, and …
biological activities such as antioxidant, anti‐inflammatory, anti‐diabetic, antitumor, and …
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related …
P Shen, Y Wang, X Jia, P Xu, L Qin, X Feng, Z Li… - European journal of …, 2022 - Elsevier
Janus kinases (JAKs) are the non-receptor tyrosine kinases covering JAK1, JAK2, JAK3,
and TYK2 which regulate signal transductions of hematopoietic cytokines and growth factors …
and TYK2 which regulate signal transductions of hematopoietic cytokines and growth factors …
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V Novotny-Diermayr, S Hart, KC Goh, A Cheong… - Blood cancer …, 2012 - nature.com
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not
well tolerated in many elderly patients, hence the unmet medical need for effective therapies …
well tolerated in many elderly patients, hence the unmet medical need for effective therapies …
Role of epigenetics in chronic myeloid leukemia
K Machova Polakova, J Koblihova, T Stopka - Current hematologic …, 2013 - Springer
The efficacy of therapeutic modalities in chronic myeloid leukemia (CML) depends on both
genetic and epigenetic mechanisms. This review focuses on epigenetic mechanisms …
genetic and epigenetic mechanisms. This review focuses on epigenetic mechanisms …
HDAC inhibitors: Promising agents for leukemia treatment
Y Deng, Q Cheng, J He - Biochemical and Biophysical Research …, 2023 - Elsevier
The essential role of epigenetic modification in the pathogenesis of a series of cancers have
gradually been recognized. Histone deacetylase (HDACs), as well-known epigenetic …
gradually been recognized. Histone deacetylase (HDACs), as well-known epigenetic …
Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways
J Petiti, V Rosso, M Lo Iacono… - Journal of Cellular …, 2019 - Wiley Online Library
Myeloproliferative neoplasms are chronic myeloid cancers divided in Philadelphia positive
and negative. The JAK2 V617F is the most common mutation in Philadelphia negative …
and negative. The JAK2 V617F is the most common mutation in Philadelphia negative …
[HTML][HTML] Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance
SH Lee, C Yoo, S Im, JH Jung, HJ Choi… - International journal of …, 2014 - ncbi.nlm.nih.gov
Background: Histone deacetylase inhibitors are a new class of drugs used in treatment of
malignant tumors. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell …
malignant tumors. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell …
STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis
C Kosan, T Ginter, T Heinzel, OH Krämer - JAK-STAT, 2013 - Taylor & Francis
The cytokine-inducible transcription factors signal transducer and activator of transcription
5A and 5B (STAT5A and STAT5B) are important for the proper development of multicellular …
5A and 5B (STAT5A and STAT5B) are important for the proper development of multicellular …
Analysis of class I and II histone deacetylase gene expression in human leukemia
H Yang, S Maddipoti, A Quesada… - Leukemia & …, 2015 - Taylor & Francis
Histone deacetylase (HDAC) inhibitors are well-characterized anti-leukemia agents and
HDAC gene expression deregulation has been reported in various types of cancers. This …
HDAC gene expression deregulation has been reported in various types of cancers. This …